ReviewWorld journal of gastroenterology2008
Primary sclerosing cholangitis--what is the difference between east and west?
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Clinical guidelines for primary sclerosing cholangitis 2017.Journal of gastroenterology · 2018Guideline
- Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn's Disease: A Case Report and Review of the Literature.Open access rheumatology : research and reviews · 2020Article
- Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.Journal of clinical medicine research · 2019Review
- Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.Gut and liver · 2018Review
- Efficacy of ustekinumab against infliximab-induced psoriasis and arthritis associated with Crohn's disease.Biologics : targets & therapy · 2018Article
- Primary sclerosing cholangitis: A review and update.Liver research (Beijing, China) · 2017Article
- Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.World journal of gastroenterology · 2015Review
- Frequency and risk factors of primary sclerosing cholangitis among patients with inflammatory bowel disease in North-East of Iran.Gastroenterology and hepatology from bed to bench · 2015Article
- A morphological and immunohistochemical study of the effects of prednisolone or ursodeoxycholic acid on liver histology in feline lymphocytic cholangitis.Journal of feline medicine and surgery · 2014Article
- Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity?World journal of gastroenterology · 2014Review
- Epidemiology and clinical course of Crohn's disease: results from observational studies.World journal of gastroenterology · 2012Review
- Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.World journal of gastroenterology · 2012Review
- Successful low-dose azathioprine for myasthenia gravis despite hepatopathy from primary sclerosing cholangitis: a case report.Journal of medical case reports · 2010Article
- The immunobiology of primary sclerosing cholangitis.Seminars in immunopathology · 2009Review
- Association between serum IgE level and adverse clinical endpoints in primary sclerosing cholangitis.Annals of hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic, progressive, cholestatic liver disease characterized by inflammation and fibrotic obliteration of the hepatic biliary tree. It is commonly associated with inflammatory bowel disease (IBD). A number of complications can occur which require special consideration, the most important of which is the development of cholangiocellular carcinoma (CCC). Unfortunately, no medical therapy is currently available for the underlying liver disease. Liver transplantation is an effective, life-extending option for patients with advanced PSC. Geographical variations between East and West include a second peak for age with a lower association with IBD in a Japanese population and female predominance in a lone study from Turkey. The clinical and biochemical Mayo criteria may not be universally applicable, as different patients show variations regarding the initial presentation and natural course of the disease. Directing research towards explaining these geographical differences and understanding the pathogenesis of PSC is required in order to develop better therapies for this devastating disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.